Early detection of pancreatic cancer: current state and future opportunities.
Early detection of pancreatic cancer: current state and future opportunities.
复制标题
胰腺癌的早期检测：现状和未来的机会。
DOI：
10.1097/mog.0000000000000770
复制
发表时间：
2021-09-01
影响因子：
2.5
通讯作者：
Majumder S
中科院分区：
文献类型：
--
作者：
Trikudanathan G;Lou E;Maitra A;Majumder S
胰腺导管腺癌（PDAC）是美国癌症死亡的第三大原因，是一种没有筛查策略的致命疾病。虽然早期诊断与生存率改善相关，但PDAC的临床检测通常处于晚期症状阶段，此时最佳治疗对生存率的影响有限。近年来，新的危险因素、早期疾病的分子标志物和胰腺成像技术的创新对这一现状提出了挑战。现在专家们一致认为，筛查可以在一组个体中进行，这些个体基于遗传和家族风险发展为PDAC的可能性增加。本文综述了已知的危险因素PDAC，目前的知识和最近的观察有关PDAC在这些风险群体的早期检测，并概述了未来的方法，将有可能推进该领域。
Pancreatic ductal adenocarcinoma (PDAC) is third leading cause of cancer death in the United States, a lethal disease with no screening strategy. Although diagnosis at an early stage is associated with improved survival, clinical detection of PDAC is typically at an advanced symptomatic stage when best in class therapies have limited impact on survival. In recent years this status quo has been challenged by the identification of novel risk factors, molecular markers of early-stage disease and innovations in pancreatic imaging. There is now expert consensus that screening may be pursued in a cohort of individuals with increased likelihood of developing PDAC based on genetic and familial risk. This review summarizes the known risk factors of PDAC, current knowledge and recent observations pertinent to early detection of PDAC in these risk groups and outlines future approaches that will potentially advance the field.